
    
      OUTLINE:

      Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28. Treatment repeats
      every 28 days for up to 6 cycles with an option to continue for up to 24 cycles in the
      absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then
      periodically thereafter.
    
  